These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12517502)

  • 61. [Immunohistochemical markers in colorectal cancer].
    Lindebjerg J
    Ugeskr Laeger; 2005 Oct; 167(44):4168-70. PubMed ID: 16266569
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
    Hebbar M; Wacrenier A; Desauw C; Romano O; Cattan S; Triboulet JP; Pruvot FR
    Anticancer Drugs; 2006 Aug; 17(7):855-7. PubMed ID: 16926635
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice.
    Hardy B; Morgenstern S; Raiter A; Rodionov G; Fadaeev L; Niv Y
    Cancer Lett; 2005 Nov; 229(2):217-22. PubMed ID: 16122870
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.
    Lau SC; Chung V; Lim D; Shibata S
    J Oncol Pharm Pract; 2014 Apr; 20(2):83-7. PubMed ID: 23353714
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C; Cunningham D
    Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monoclonal antibody treatment of colorectal cancer.
    Pullyblank AM; Monson JR
    Br J Surg; 1997 Nov; 84(11):1511-7. PubMed ID: 9393269
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Tumor targeting in colon cancer. Antibody therapy--a new adjuvant application].
    Chirurg; 1995 Jul; 66(7 Suppl):1-4. PubMed ID: 9131058
    [No Abstract]   [Full Text] [Related]  

  • 69. Minimal residual disease as the target for immunotherapy of cancer.
    Nossal GJ
    Lancet; 1994 May; 343(8907):1172-4. PubMed ID: 7909862
    [No Abstract]   [Full Text] [Related]  

  • 70. Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.
    Seeber A; Martowicz A; Spizzo G; Buratti T; Obrist P; Fong D; Gastl G; Untergasser G
    BMC Cancer; 2015 May; 15():372. PubMed ID: 25947366
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Edrecolomab in the adjuvant treatment of colorectal carcinoma.
    Spizzo G; Obrist P; Went P; Dirnhofer S; Gastl G
    Lancet; 2003 Jan; 361(9351):83; author reply 83. PubMed ID: 12517502
    [No Abstract]   [Full Text] [Related]  

  • 72. Edrecolomab in the adjuvant treatment of colorectal carcinoma.
    Alliot C
    Lancet; 2003 Jan; 361(9351):82; author reply 83. PubMed ID: 12517501
    [No Abstract]   [Full Text] [Related]  

  • 73. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.
    Schwartzberg LS
    Crit Rev Oncol Hematol; 2001 Oct; 40(1):17-24. PubMed ID: 11578913
    [TBL] [Abstract][Full Text] [Related]  

  • 74. When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab.
    Schmoll HJ; Arnold D
    J Clin Oncol; 2009 Apr; 27(12):1926-9. PubMed ID: 19273695
    [No Abstract]   [Full Text] [Related]  

  • 75. Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer.
    Gambill BD
    Clin Colorectal Cancer; 2001 May; 1(1):16-7. PubMed ID: 12445374
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.